Thiazolidinedione (TZD) compounds, such as rosiglitazone (ROSI), pioglitazone (PIO), and troglitazone (TRO), reduced the mortality of mice after GPX4 was loss by inhibiting the action of ACSL4, indicating that these compounds may show potential therapeutic effects on AKI [43, 48]. Here, ACSL4 is linked to acute kidney injury.